Sign up
Pharma Capital

Ventripoint Diagnostics shares rise as it gains major customer for complete heart analysis system

The University of Ottawa Heart Institute, Canada’s largest heart health centre, will use Ventripoint’s system to assess cardiac patients
doctor holding heart
The Toronto-based health care company’s system uses artificial intelligence to streamline volumetric measurements and ejection fractions for all four heart chambers

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) gained a major new customer for its VMS+ complete heart analysis system on Monday.

The University of Ottawa Heart Institute, the largest heart health centre in Canada, ordered Ventripoint’s system to use in clinical assessment of cardiac patients.

The new system will be used for research into valvular heart disease, infective endocarditis and aortic diseases, with a specific focus on the application of ultrasound in the study of cardiac structure and function, the company said in a statement.

Shares of Ventripoint jumped nearly 6% Monday to C$0.18 in Toronto, and traded at US$0.13 in the US.

READ: Ventripoint showcases its latest VMS+3.0 cardio-monitoring system at American College of Cardiology's 68th Annual conference

The Toronto-based health care company’s system uses artificial intelligence to streamline volumetric measurements and ejection fractions for all four heart chambers from standard two-dimensional images.

The results are equivalent to those from standard MRI testing, the only approved method currently on the market.

Initial research will test the hypothesis that right ventricular volume determined by Ventripoint’s system can be used as a more reliable and quantitative method to assess patients with tricuspid regurgitation.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

1553005391_Angela2.jpg


Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.